Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.33 |
| ▸ | BDNF | P23560 | 3/20 | 0.32 |
| ▸ | PTN | P21246 | 2/20 | 0.32 |
| ▸ | MDK | P21741 | 2/20 | 0.32 |
| ▸ | IARS1 | P41252 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CD69 | Q07108 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123871 | 0.89 | OGA (0.32) | OGABDNFPTNMDK | |
| SCHEMBL30980651 | 0.82 | OGA (0.36) | OGAIARS1 | |
| SCHEMBL16250370 | 0.81 | OGA (0.36) | OGA | |
| SCHEMBL12355191 | 0.81 | IARS1 (0.33) | IARS1 | |
| SCHEMBL14478983 | 0.81 | IARS1 (0.33) | IARS1 | |
| SCHEMBL9976875 | 0.81 | IARS1 (0.33) | IARS1 | |
| SCHEMBL25499753 | 0.79 | ALDH1A1 (0.35) | OGACD69 | |
| SCHEMBL23705039 | 0.77 | OGA (0.46) | OGACD69 | |
| SCHEMBL24916748 | 0.77 | OGA (0.39) | OGACYP2C9CYP2C19 | |
| SCHEMBL12178004 | 0.77 | OGA (0.46) | OGACD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | OGA 76/4885BDNF 1751/4885PTN 3287/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | OGA 68/4885BDNF 1731/4885PTN 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.